"Phthalazines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Bicyclic heterocyclic compounds containing a BENZENE ring fused to PYRIDAZINE.
| Descriptor ID |
D010793
|
| MeSH Number(s) |
D03.383.710.605
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Phthalazines".
Below are MeSH descriptors whose meaning is more specific than "Phthalazines".
This graph shows the total number of publications written about "Phthalazines" by people in this website by year, and whether "Phthalazines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 2 | 1 | 3 |
| 2019 | 2 | 0 | 2 |
| 2020 | 2 | 1 | 3 |
| 2021 | 2 | 2 | 4 |
| 2022 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Phthalazines" by people in Profiles.
-
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial. Ann Oncol. 2024 Nov; 35(11):981-992.
-
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early?breast cancer. Ann Oncol. 2022 Dec; 33(12):1250-1268.
-
Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer. Eur J Cancer. 2021 11; 157:415-423.
-
Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial. Gynecol Oncol. 2021 10; 163(1):41-49.
-
PARP inhibitor associated treatment related myeloid neoplasms: What was a "Rare" complication may be less so. Gynecol Oncol. 2021 06; 161(3):639-641.
-
Promoter methylation of DNA homologous recombination genes is predictive of the responsiveness to PARP inhibitor treatment in testicular germ cell tumors. Mol Oncol. 2021 04; 15(4):846-865.
-
Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States. Gynecol Oncol. 2020 11; 159(2):491-497.
-
PARP inhibitors in castration-resistant prostate cancer. Cancer Treat Res Commun. 2020; 24:100199.
-
Effects of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Cerulein-Induced Pancreatitis. Shock. 2020 05; 53(5):653-665.
-
PARP Inhibition Enhances Radiotherapy of SMAD4-Deficient Human Head and Neck Squamous Cell Carcinomas in Experimental Models. Clin Cancer Res. 2020 06 15; 26(12):3058-3070.